for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Autolus Therapeutics PLC

AUTL.OQ

Latest Trade

10.63USD

Change

-0.27(-2.43%)

Volume

6,362

Today's Range

10.58

 - 

10.93

52 Week Range

3.00

 - 

17.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.89
Open
10.93
Volume
6,362
3M AVG Volume
1.60
Today's High
10.93
Today's Low
10.58
52 Week High
17.19
52 Week Low
3.00
Shares Out (MIL)
52.30
Market Cap (MIL)
569.53
Forward P/E
-4.05
Dividend (Yield %)
--

Next Event

Autolus Therapeutics plc - Special Call

Latest Developments

More

Autolus Therapeutics Q3 Loss Per Share $0.72

Autolus Therapeutics Q2 Loss Per Share $0.62

Autolus Therapeutics Q1 Loss Per Share $0.60

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Autolus Therapeutics PLC

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

Industry

Biotechnology & Drugs

Contact Info

Scale Space Building

White City, 58 Wood Lane

W12 7RZ

United Kingdom

+44.20.38296230

https://www.autolus.com/

Key Stats

1.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-2.780

2020(E)

-2.690
Price To Earnings (TTM)
--
Price To Sales (TTM)
460.42
Price To Book (MRQ)
2.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.86
Return on Equity (TTM)
-39.63

Latest News

Latest News

BRIEF-Autolus Therapeutics Presents New Preclinical Data During The Virtual 2020 Aacr Annual Meeting

* AUTOLUS THERAPEUTICS PRESENTS NEW PRECLINICAL DATA DURING THE VIRTUAL 2020 AACR ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Autolus Therapeutics Presents Additional Data On Auto3 In DLBCL During ASCO20 Virtual Scientific Program

* AUTOLUS THERAPEUTICS PRESENTS ADDITIONAL DATA ON AUTO3 IN DLBCL DURING THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Autolus Therapeutics Q1 Loss Per Share $0.60

* AUTOLUS THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

BRIEF-Autolus Therapeutics Announces FDA Acceptance Of Ind Application For Auto1 For Adult Acute Lymphoblastic Leukemia

* AUTOLUS THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR AUTO1 FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

BRIEF-Molmed Signs Agreement With Autolus Therapeutics

* SIGNS AGREEMENT WITH AUTOLUS THERAPEUTICS FOR COOPERATION IN FIELD OF T-CELL THERAPIES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Autolus Therapeutics PLC FY Loss Per Share $2.88

* AUTOLUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

BRIEF-Autolus Therapeutics Reports Qtrly Loss Per Share $2.88

* AUTOLUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up